Protocol Ledger

NCT06401980 · Phase II · RECRUITING

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventional Phase II clinical trial protocol NCT06401980 sponsored by Swiss Cancer Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-22 Enrollment: 162 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06401980
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)162 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06401980
Protocol FieldVerified Registry Value
NCT IdentifierNCT06401980
Consolidated Lead SponsorSwiss Cancer Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment162 participants (ESTIMATED)
Registered Start Date2024-10-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06401980
Hospital Research SiteLocationSite Profile
Kantonsspital St. GallenSankt Gallen, SwitzerlandOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI